Hemera Biosciences

Developing HMR59, an intravitreal gene therapy, to preserve vision in eyes with dry age-related macular degeneration.

[Xtalks Webinars @Xtalks]

@JanssenUS has acquired the rights to a gene therapy for age-related macular degeneration from @HemeraBio. Read more by @AyeshaR1202 here.
https://t.co/BTgMW2rGq3
#GeneTherapy #AgingPopulation #VisionLoss

[Plexus Ventures @PlexusVentures]

#Janssen buys up #eyedisorder #genetherapy asset from #HemeraBiosciences https://t.co/vqcIxSuqIP @FierceBiotech @JanssenGlobal @HemeraBio

[pharmaphorum @pharmaphorum]

.@JNJNews pharma unit @JanssenGlobal has bought rights to an investigational gene therapy for a severe form age-related macular degeneration from specialist biotech @HemeraBio https://t.co/G0yRmG5Qbl #pharma #ophthalmology

[BioSpace @biospace]

@JanssenUS Acquires Rights to @HemeraBio's Macular Degeneration Gene Therapy

#biospace #lifesciences #biotechnology #pharmaceuticals

https://t.co/mvcQrSAsAM

[[iito] Life Science @iitoLifeScience]

Janssen Acquires Rights to Novel Gene Therapy, from Hemera Biosciences, for Late-Stage Age-Related Macular Degeneration https://t.co/kAYP376gra @JanssenUS @JanssenEMEA @HemeraBio More U.S. Life Science Business News at [LSUS] at https://t.co/fO8Gniaszr

[J&J Innovative Medicine @JNJInnovMed]

Janssen acquires rights to novel, investigational gene therapy from @HemeraBio to help preserve vision in patients with geographic atrophy, a late-stage form of age-related macular degeneration. Click for more: https://t.co/srFok73AX2

[J&J Innovative Medicine @JNJInnovMed]

We are thrilled to announce the #acquisition of rights to an investigational #genetherapy to preserve vision in patients with #geographicatrophy from @HemeraBio. Details here: https://t.co/JkKcQ0Jw8W

[Hemera Biosciences @HemeraBio]

We are thrilled to announce that @JanssenGlobal has acquired the rights to the HMR59 #genetherapy to preserve vision in patients with #geographicatrophy. Details available https://t.co/G9pPfOOnZJ and https://t.co/UF9ffNac0q

[J&J Innovative Medicine @JNJInnovMed]

We are thrilled to announce the #acquisition of rights to an investigational #genetherapy to preserve vision in patients with #geographicatrophy from @HemeraBio. Details here: https://t.co/gKXlCHNlgN

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

THREAD: There's a growing body of data to strongly suggest #COVID19 predisposes to both venous and arterial thromboembolism due to excessive inflammation, hypoxia, immobilization and diffuse intravascular coagulation. This may explain some of rapid decline patients experience 1/n

[SY Investing @syinvesting]

Good article on #GeneTherapy for #ophthalmology, with a focus on #AMD: https://t.co/VjyzNJSiip

$ADVM $RGNX $SNY $OXB @GyroscopeTx @HemeraBio

[Hemera Biosciences @HemeraBio]

Founder Elias Reichel reporting 12 month dry and early wet AMD study results after a single dose of HMR59 @RetinaWCongress

[Hemera Biosciences @HemeraBio]

Hemera founder Jay Duker discussing use of HMR59 to block complement for #dryAMD and future use at early stages of AMD before vision loss occurs @RetinaWCongress

[Hemera Biosciences @HemeraBio]

@DominicSchmidt Phase 1 safety study with the graph showing 9 high dose eyes compared to a natural history study of dry AMD with GA.

[Hemera Biosciences @HemeraBio]

Hemera founder Jay Duker presenting Hemera 12 month dry AMD data at Angiogenesis meeting in Miami showing reduction vs natural history after a single injection of HMR59 at Day 0. Wet AMD study using HMR59 continues to enroll.

[Hemera Biosciences @HemeraBio]

Given the rapid enrollment of HMR-1002 for new onset #wetAMD using HMR59 #genetherapy we have expanded enrollment up to 25 patients. Enrollment information available at https://t.co/7nafpxEFg6

[Hemera Biosciences @HemeraBio]

As 2018 winds down Hemera thanks all the patients and clinical sites making our #genetherapy trials for #maculardegeneration HMR1001 (Dry AMD) and HMR1002 (Wet AMD) an enormous success.

[Hemera Biosciences @HemeraBio]

Hemera’s wet AMD study HMR-1002 using HMR59 following a single antiVEGF injection enrolled 10 patients in 3 months. Will expand enrollment in 2019.

[Hemera Biosciences @HemeraBio]

@mhanewich @bexley1988 @mhanewich thanks. Just enrolled patient #1 today.

[Hemera Biosciences @HemeraBio]

HMR-1002 treating patients with new onset wet AMD using Hemera’s gene therapy HMR59 is open and has enrolled the first patient today. Info @ https://t.co/7nafpxEFg6